Tango Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Tango Therapeutics

08/08/2023 14:33

* Tango Therapeutics Inc  TNGX.OQ  reported a quarterly
adjusted
loss of 23 cents​​ per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 34 cents per share.
    * Revenue rose 153% to $14.60 million from a year ago;
analysts
expected $6.95 million. 
    * Tango Therapeutics Inc's reported EPS for the quarter was
a loss
of 23 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Tango Therapeutics Inc shares had risen by 3.6% this
quarter and
lost 52.6% so far this year.
    * The company reported a quarterly loss of $20.71 million.
    * Wall Street's median 12-month price target for Tango
Therapeutics Inc is $14.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.34          -0.23          Beat
 Mar. 31 2023      -0.35          -0.32          Beat
 Dec. 31 2022      -0.35          -0.33          Beat
 Sep. 30 2022      -0.32          -0.33          Missed